Zacks Research Upgrades AC Immune (NASDAQ:ACIU) to “Strong-Buy”

AC Immune (NASDAQ:ACIU) was upgraded by investment analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a note issued to investors on Tuesday, Zacks reports.

A number of other equities research analysts have also issued reports on ACIU. BTIG Research reissued a “buy” rating and issued a $8.00 target price on shares of AC Immune in a research report on Wednesday, September 23rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of AC Immune in a research report on Wednesday, August 5th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of AC Immune in a research note on Thursday, September 24th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, AC Immune presently has an average rating of “Moderate Buy” and an average price target of $7.50.

AC Immune Stock Up 0.8%

AC Immune stock opened at $2.62 on Tuesday. The company has a 50 day moving average of $2.59 and a 200-day moving average of $2.67. The company has a quick ratio of 1.02, a current ratio of 0.93 and a debt-to-equity ratio of 0.11. AC Immune has a twelve month low of $2.10 and a twelve month high of $4.00. The stock has a market capitalization of $266.64 million, a PE ratio of -4.85 and a beta of 1.60.

AC Immune (NASDAQ:ACIU) last announced its earnings results on Thursday, August 6th. The company reported $0.03 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.13. The firm had revenue of $18.67 million during the quarter, compared to analyst estimates of $9.59 million. AC Immune had a negative net margin of 245.32% and a negative return on equity of 100.17%. On average, equities research analysts anticipate that AC Immune will post -0.6 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. AXQ Capital LP bought a new position in shares of AC Immune in the second quarter valued at $25,000. Arrowstreet Capital Limited Partnership increased its holdings in AC Immune by 8.0% during the first quarter. Arrowstreet Capital Limited Partnership now owns 405,658 shares of the company’s stock worth $1,116,000 after buying an additional 30,035 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its position in AC Immune by 82.8% during the first quarter. Dimensional Fund Advisors LP now owns 390,165 shares of the company’s stock worth $1,071,000 after acquiring an additional 176,701 shares in the last quarter. 51.36% of the stock is currently owned by institutional investors.

About AC Immune

AC Immune SA (NASDAQ: ACIU) is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland. Founded in 2003, the company develops precision medicines and diagnostic products designed to prevent, diagnose and treat neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease and other conditions associated with misfolded proteins.

AC Immune’s research is based on its SupraAntigen and Morphomer technology platforms, which are intended to identify disease-related proteins and generate therapies or diagnostic tools that target them.